Importantly, the pharmacological analysis of the MEK inhibitors Mirdametinib and Trametinib did not reveal KRAS mutations as a positive predictive factor, which is contrary to retrospectively analyzed findings of a study of binimetinib plus capecitabine in CCA patients, where RAS/RAF/MEK/ERK pathway mutations showed significantly better tumor response, PFS and OS [26]. This evidence concerns the gene KRAS and cholangiocarcinoma.